Is Asia-Pacific on Track Towards Elimination of Malaria by 2030?
Table of Contents
Relevance:
GS Paper II – Health, Governance, International Cooperation
GS Paper III – Public Health, Science & Technology, Development Challenges
Important Keywords
For Prelims:
- Malaria Elimination, World Malaria Report 2025, Artemisinin-based Combination Therapy (ACT), Drug Resistance, RTS,S Vaccine, R21 Vaccine, Surveillance, Plasmodium falciparum
For Mains:
- Public Health Systems, Disease Elimination, Antimicrobial Resistance, Global Health Governance, Health Financing, Regional Cooperation
Why in News?
The World Malaria Report 2025, released in December, assessed global and regional progress towards the 2030 malaria elimination target. While the Asia-Pacific region showed encouraging declines in malaria cases, rising artemisinin resistance and declining funding for malaria programmes raised serious concerns about meeting elimination timelines.
Global and Asia-Pacific Malaria Scenario
Globally, malaria elimination progress remains uneven. However, the Asia-Pacific region emerged as a relative bright spot, accounting for much of the reduction in estimated cases over the past year, even as other regions struggled with stagnation or resurgence.
Malaria
- Malaria is a life-threatening parasitic disease caused by Plasmodium parasites.
- It is transmitted through the bite of infected female Anopheles mosquitoes.
- The parasite is a protozoan.
Causative Parasites (Plasmodium Species)
- Plasmodium falciparum – Most deadly form (common in Africa & India)
- Plasmodium vivax – Common in India & Asia
- Plasmodium malariae
- Plasmodium ovale
In India, the most common species are:
- P. falciparum
- P. vivax
Incubation Period
- Symptoms usually appear 10–14 days after mosquito bite.
Life Cycle in Humans
- Parasite undergoes development in:
- Liver cells → Pre-erythrocytic schizogony
- Red Blood Cells (RBCs) → Erythrocytic schizogony
- Causes fever, chills, anemia, and organ complications.
Most Dangerous Type
- Plasmodium falciparum infection:
- Causes severe malaria
- Can lead to brain malaria, organ failure, death
Diagnosis
- Microscopy (blood smear test)
- Rapid Diagnostic Tests (RDTs)
Treatment
- Artemisinin-based Combination Therapy (ACT) – First-line treatment
- Resistance to artemisinin = global public health concern
Prevention Measures
- Insecticide-treated bed nets (ITNs)
- Indoor Residual Spraying (IRS)
- Larval source management
- Vaccines: RTS,S and R21 (new)
Progress in Asia-Pacific Region
- Of the 17 malaria-endemic countries in Asia-Pacific, 10 recorded significant declines.
- Estimated malaria cases reduced from 9.6 million (2023) to 8.9 million (2024).
- Major reductions observed in Pakistan.
- Historic lows reported for the second consecutive year in:
- Cambodia
- Lao PDR
- Vietnam
- The Greater Mekong Subregion demonstrated notable success in tackling antimalarial drug resistance.
Emerging Challenges: Drug Resistance
- Rising resistance to artemisinin-based frontline treatment is a serious global threat.
- Resistance has been particularly reported in parts of Southeast Asia.
- Drug resistance threatens decades of progress by increasing treatment failures and mortality.
Financing Gaps and Programme Risks
- Only 42% of global malaria financing needs were met in 2024.
- Funding cuts in 2025 further widened the gap.
- Reduced financing forces countries to:
- Scale back proven interventions
- Increase risk of resurgence
- Reverse hard-won public health gains
India’s Elimination Target and Current Status
- India aims to achieve zero indigenous malaria cases by 2027, ahead of the global 2030 target.
- Significant progress since 2015:
- Sharp reductions in cases and deaths
- Several districts reporting sustained zero transmission
- However:
- Progress has plateaued recently
- Cases have rebounded in certain regions
- India is currently off the elimination trajectory needed to meet the 2027 goal
Critical Shifts Needed for Elimination
Three key shifts are essential for moving from control to elimination:
a) Surveillance as the Core Intervention
- Real-time, case-based surveillance across:
- Private healthcare sector
- Defence services
- Railways
- Urban health systems
b) Focus on Remaining Hotspots
- Five States and the Northeast account for ~80% of India’s malaria burden.
- Requires project-mode execution in high-burden areas.
- Near-elimination States must prevent resurgence.
c) Sustained Financing and Accountability
- Malaria elimination must be treated as a time-bound national mission.
- Requires sustained investment, strict accountability and last-mile execution.
- Real-time, case-based surveillance across:
Role of Vaccines in Malaria Control
RTS,S vaccine:
- Proven reduction in severe malaria and child mortality in African pilots.
R21 vaccine:
Comparable or higher efficacy in trials.
Vaccines currently prioritised for Africa, given higher burden.
Asia-Pacific countries are evaluating targeted deployment as a complementary tool.
Artemisinin Resistance: India’s Position
- Artemisinin resistance not yet established in India.
- India’s preventive measures include:
- Regular therapeutic efficacy studies
- Strong pharmacovigilance
- Rapid updating of treatment protocols
- Ban on oral artemisinin monotherapy
- Emphasis on:
- Universal parasitological diagnosis
- Strict adherence to combination therapy
Vulnerable Populations and Last-Mile Challenges
- High-risk groups include:
- Migrant and mobile populations
- Remote and geographically isolated communities
- Challenges:
- Limited access to healthcare
- Weak outreach by conventional malaria programmes
Way Forward
- Strengthen regional coordination to prevent cross-border spread.
- Protect artemisinin through:
- Strict drug regulation
- Community-level case management
- Increase domestic financing alongside global support.
- Treat malaria elimination as an investment, not expenditure:
- Reduced healthcare costs
- Increased productivity
- Improved community resilience
Conclusion
The Asia-Pacific region has demonstrated that malaria elimination is achievable, but progress remains fragile and uneven. Rising drug resistance, financing shortfalls and last-mile challenges threaten to derail the 2030 goal. Sustained political commitment, robust surveillance, regional cooperation and assured financing are essential to convert current gains into lasting elimination. Failure at this stage would not only reverse progress but impose far greater economic and human costs in the future.
UPSC PYQ
Q. Which of the following pairs is/are correctly matched?
- Malaria : Mycobacterium
- Tuberculosis (TB) : Plasmodium
-
- 1 only
- 2 only
- Both 1 and 2
- Neither 1 nor 2
- Pair 1 is incorrect: Malaria is caused by protozoan parasites of the genus Plasmodium, not Mycobacterium.
- Pair 2 is incorrect: Tuberculosis is caused by Mycobacterium tuberculosis, not Plasmodium.
CARE MCQ
Q. Which of the following statements correctly describes malaria?
- It is a bacterial disease transmitted by the bite of Aedes mosquito
- It is a parasitic disease caused by Plasmodium species and transmitted by female Anopheles mosquito
- It is a viral disease in which infection occurs directly in red blood cells only
- It is a fungal disease with an incubation period of more than one month
- Malaria is a life-threatening parasitic disease caused by protozoan parasites of the genus Plasmodium.
- It is transmitted through the infective bite of the female Anopheles mosquito.
- In humans, the parasite completes part of its life cycle in the liver (pre-erythrocytic stage) and red blood cells (erythrocytic stage).
- Among the species, Plasmodium falciparum is responsible for the most severe and deadly form of malaria, especially common in tropical regions like India.
